GLP-1
The FDA Just Permanently Ended Bulk Compounded GLP-1s
The FDA's April 30, 2026 proposed rule permanently closes the door on bulk compounded GLP-1s. Here's what that means for your peptide therapy protocol — and your real options.
GLP-1
The FDA's April 30, 2026 proposed rule permanently closes the door on bulk compounded GLP-1s. Here's what that means for your peptide therapy protocol — and your real options.
MOTS-c
MOTS-c is the only peptide with two human trials. One proved it worked — then the company dissolved. The second is running. July 23, the FDA decides compounding access.